These 10 traditional Chinese medicine injections are amazing! The reason why the list of new and old base drugs can't be changed is

On October 25, the national catalogue of essential drugs (2018 Edition) was officially released, and it will be implemented as of November 1 It is reported that of the 520 varieties in the 2012 version of the basic drug catalog, Chinese patent medicines accounted for 203 varieties, while the number of Chinese patent medicines in the 2018 version of the basic drug catalog increased to 268 varieties In the two versions of the catalogue, none of the 10 traditional Chinese medicine injections has been transferred What's the reason? Table 1: details of the traditional Chinese medicine injections in the 2012 and 2018 versions of the basic Chinese medicine catalogue (Note: △ "indicates that the drugs should be used under the guidance of doctors with corresponding prescription qualifications or under the guidance of specialists, and strengthen the use monitoring and evaluation) 3 of the 10 traditional Chinese medicine injections are 1 billion varieties Table 2: Sales of 10 traditional Chinese medicine injections (unit: 10000 yuan) (source: minenet database) On September 5, Zeng Yixin, deputy director of the national health and Health Commission, introduced the work related to the improvement of the national essential drug system at the regular policy briefing of the State Council, saying, "in the selection of the catalogue, we should pay more attention to the clinical value of the drugs, adhere to dynamic adjustment, and attach equal importance to both transfer in and transfer out The ones to be included in the catalogue of essential drugs can be newly approved and listed, with higher prices, but with better effects Good drugs can better meet the needs of the people's clinical disease prevention and treatment " The new version of the basic drug catalogue does not introduce new varieties of traditional Chinese medicine injections, which can be understood as a cautious attitude towards adverse reactions that have been plaguing the industry at the national level; In addition, the new base drug catalogue also added restrictions on the use of these 10 traditional Chinese medicine injections, "which should be used under the guidance of doctors with corresponding prescription qualifications or under the guidance of specialists and strengthen the use monitoring and evaluation", with the intention of strengthening management There is no transfer out of 10 injections in the old catalog, indicating that these products have been accepted by the industry and patients in terms of clinical value, effect, price, etc According to the data of mienei.com, in 2017, the sales of these 10 traditional Chinese medicine injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminals exceeded 1 billion yuan in three products, and in addition, there were six products with sales exceeding 100 million yuan Among the 10 traditional Chinese medicine injections, there are two exclusive products, respectively, Xueshuantong (freeze-dried) for injection of Zhongheng group and Mailuoning injection of Jinling pharmaceutical, which are used for cerebrovascular diseases Two directions at the national level: support and supervise the interpretation of the national essential drugs catalogue (2018 Edition), which mentioned that the CPC Central Committee and the State Council attach great importance to the development of traditional Chinese medicine In the national drug policy and basic drug system and other related work, the national health and health Commission pays attention to reflect the characteristics of traditional Chinese medicine, play the role of traditional Chinese medicine, and promote the development of traditional Chinese medicine The measures for the administration of national essential drugs catalogue (gwyzf [2015] No 52) clearly stipulates that when selecting national essential drugs, both Chinese and Western medicines should be emphasized The adjustment principles determined in the work plan of this catalog adjustment also clearly need to support the development of traditional Chinese medicine Traditional Chinese medicine injection is based on the theory and experience of traditional Chinese medicine, using modern science and technology and methods to extract effective substances from traditional Chinese medicine or other natural medicines Traditional Chinese medicine injection originated in the war time when drugs were extremely scarce, and it is the outstanding product of the modernization of traditional Chinese medicine in China With the wide application of traditional Chinese medicine injection in clinical practice, the whole sub industry has developed rapidly According to the data of miintranet, since 2016, the market scale of terminal traditional Chinese medicine injection in public medical institutions in China has exceeded 100 billion In 2017, the sales volume was 102 billion 150 million yuan, and the growth rate affected by the policy dropped by 2.52% Figure 1: sales volume of terminal traditional Chinese medicine injection of public medical institutions in China from 2013 to 2017 (unit: 10000 yuan) (source: minenet China public medical institutions terminal competition pattern) In recent years, adverse reactions of traditional Chinese medicine injections have been reported from time to time The public opinion and the industry have launched a heated discussion on the safety of traditional Chinese medicine injections, and relevant departments have begun to strengthen the supervision of traditional Chinese medicine injections from the policy level 2017 is the most concerned year for traditional Chinese medicine injection The 2017 version of the national medical insurance catalogue issued by the Ministry of human resources and social security clearly states that 26 kinds of traditional Chinese medicine injection are only used in secondary and above medical institutions, which gives traditional Chinese medicine injection a heavy blow Subsequently, the State Food and Drug Administration successively issued announcements to revise the instructions of several traditional Chinese medicine injections: on November 28, 2017, Shengmai injection instructions were revised; on April 28, 2018, Shenmai injection instructions were revised; on May 29, 2018, bupleurum injection instructions were revised; on June 12, 2018, Danshen injection instructions were revised; on June 12, 2018, Danshen injection instructions were revised On July 3, 2018, it issued the notice of revising the instructions of Qingkailing injection, on July 19, 2018, it issued the notice of revising the instructions of Xuesaitong injection, Xuesaitong Injection (lyophilized) and Xueshuantong injection, Xueshuantong injection (lyophilized) As early as 2012, the former State Food and Drug Administration issued the 48th notice on adverse drug reactions, which also mentioned that Mailuoning injection had serious allergic reaction risk, reminding the majority of medical staff to carefully inquire about the allergy history of patients when choosing drugs, and conduct full risk / benefit assessment to inform patients of possible drug risks At this point, all the top 10 traditional Chinese medicine injections in the base drug list have been strictly controlled In addition, under the pressure of medical insurance and fee control, provinces and cities have successively established key monitoring drug systems, and some regions even published the list of key monitoring drugs, in which there are many figures of traditional Chinese medicine injections It can be seen that the regulatory policies are detailed from top to bottom It seems that the policy is exerting pressure on traditional Chinese medicine injections at all levels Should it be regarded as a "deserter"? No! On March 23 this year, in the 2017 annual drug review report issued by the former State Food and drug administration, it was mentioned that China will start the re evaluation of traditional Chinese medicine injections in 2018 and formulate the technical guidelines for re evaluation Jiao hongzeng, director of the State Food and drug administration, said that the re evaluation of traditional Chinese medicine injections will be a process of "sweeping the waves" for more than 130 kinds of existing traditional Chinese medicine injections The standards of "safety and effectiveness" of products will be more reasonable evaluated under the new historical conditions, and the enterprises, varieties and brands of traditional Chinese medicine injections market will be accelerated Where is the way forward for traditional Chinese medicine injection? Shenwei pharmaceutical: injection sales increased by 70.3% in the first half of 2018 Table 3: sales growth of injection products of Shenwei pharmaceutical in 2017-2018 (data source: annual report of listed companies, China Daily) Due to the limited medical insurance catalogue in 2017, Qingkailing injection took a wait-and-see attitude in the short term, reducing purchase orders, and sales fell by 33.3% At the beginning of 2018, the domestic influenza epidemic was serious Qingkailing injection was included in the anti influenza drugs recommended by national institutions The psychological impact of primary medical institutions was gradually eliminated, and the sales volume increased significantly again The sales growth rate in the first half of 2018 was 96.6% Shenwei pharmaceutical said that Shenmai injection was originally sold to secondary and higher medical institutions through investment promotion, and nearly half of it was sold to primary medical institutions In 2018, the group took the city's third level hospitals as its academic benchmark, vigorously developed county-level public hospitals and private hospitals, and the grassroots terminal team will also lock in the hospital and the community's core customers, with the help of the hospital's platform, the terminal will sink, develop the subordinate villages and offices of the hospital, strengthen the expert lecture link, and promote the terminal drug use In the first half of 2018, sales of Shenmai injection increased by 30.2% It is reported that Shenmai injection has completed a large-scale safety re evaluation of 30000 cases Li Zhenjiang, chairman of Shenwei Pharmaceutical Co., Ltd., said in an interview that after the decline of last year's performance, enterprises should improve their control over primary medical terminals, establish a professional academic promotion team, focus on strengthening their academic promotion ability, carry out extensive training and education for primary doctors, promote the rational use of traditional Chinese medicine injection, and greatly improve the use of traditional Chinese medicine injection in primary medical institutions Jet confidence At present, Shenwei pharmaceutical industry is also proving the effectiveness and safety of traditional Chinese medicine injection through large sample research, which is also a strategy for enterprises to cope with industry changes by deepening internal skills CR Sanjiu: the proportion of traditional Chinese medicine injection in revenue dropped to 8% CR Sanjiu mentioned in the 2018 half year report that in recent years, under the pressure of auxiliary drug catalog policy and bidding price reduction, the sales and promotion of non clinical first-line drugs such as traditional Chinese medicine injection are facing difficulties The company continues to adjust the product structure and gradually extends to both ends of health care and rehabilitation After adjustment, the proportion of traditional Chinese medicine injections, which used to account for a large proportion in the prescription drug business, has gradually declined to about 8% in the operating revenue It is reported that the scientific research projects of Shenfu injection, Honghua injection and Shenmai injection have won the second prize of the national science and technology progress award CR 39 said that in 2018, it will continue to conduct in-depth research on products and continue to provide consumers with high-quality products Zhongheng group: improving safety and increasing academic promotion are affected by the limitation of traditional Chinese medicine injection regulated by the medical insurance catalog In 2017, the sales volume of Xueshuantong (freeze-dried) for injection of Zhongheng group increased by 0.6% over the previous year, and the sales volume of Xueshuantong injection decreased by 38.90% over the previous year In response to this policy, Zhongheng group said that it would strengthen the research of Xueshuantong products, improve the safety of products, and increase the academic promotion In recent years, Zhongheng group has gradually improved its R & D system, established a number of autonomous region level and national level research (R & D) centers, comprehensively deepened the innovation work of production, learning and research, carried out the re evaluation of core product Xueshuantong injection, standardized construction of Xueshuantong for injection, research and development of chemical medicine, biological medicine and other projects, and achieved high starting point and high-level innovation and development At present, the re evaluation study of Xueshuantong injection and the standardization study of Xueshuantong for injection are carried out orderly according to the requirements Zhongheng group said that there may be some pressure in the short term for the implementation of re evaluation of injection, but in the long term, it is very helpful for the improvement of injection level in China, and the injection with good effect will benefit.